BACKGROUND: miRNAs regulate gene expression, and thus play an important role in critical cellular processes. Aberrant miRNA expression patterns have been found in various types of cancer. So far, information about the expression of miRNAs in pediatric acute myeloid leukemia is limited. PROCEDURE: We studied expression of miR-29a, -155, -196a, and -196b by stem-loop based RT-qPCR in 82 pediatric acute myeloid leukemia patients selected to represent relevant cytogenetic and molecular subgroups. RESULTS: High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements (P < 0.001), NPM1 mutations (P < 0.001), or FLT3-ITD in a cytogenetically normal background (P ≤ 0.02), compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b (P ≤ 0.001). Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes (Spearman's r = 0.46-0.82, P < 0.01). Expression of miR-155 was not related to cytogenetic features but high expression of miR-155 was observed in FLT3-ITD (P = 0.001) and NPM1-mutated cases (P = 0.04). Lower miR-29a expression was mainly observed in MLL-rearranged pediatric acute myeloid leukemia, specifically in cases carrying t(10;11) (P < 0.001). CONCLUSIONS: We show aberrant expression of specific miRNAs in clinically relevant cytogenetic and molecular subgroups of pediatric acute myeloid leukemia, suggesting a role for these miRNAs in the underlying biology in these specific subgroups.
BACKGROUND: miRNAs regulate gene expression, and thus play an important role in critical cellular processes. Aberrant miRNA expression patterns have been found in various types of cancer. So far, information about the expression of miRNAs in pediatric acute myeloid leukemia is limited. PROCEDURE: We studied expression of miR-29a, -155, -196a, and -196b by stem-loop based RT-qPCR in 82 pediatric acute myeloid leukemiapatients selected to represent relevant cytogenetic and molecular subgroups. RESULTS: High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements (P < 0.001), NPM1 mutations (P < 0.001), or FLT3-ITD in a cytogenetically normal background (P ≤ 0.02), compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b (P ≤ 0.001). Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes (Spearman's r = 0.46-0.82, P < 0.01). Expression of miR-155 was not related to cytogenetic features but high expression of miR-155 was observed in FLT3-ITD (P = 0.001) and NPM1-mutated cases (P = 0.04). Lower miR-29a expression was mainly observed in MLL-rearranged pediatric acute myeloid leukemia, specifically in cases carrying t(10;11) (P < 0.001). CONCLUSIONS: We show aberrant expression of specific miRNAs in clinically relevant cytogenetic and molecular subgroups of pediatric acute myeloid leukemia, suggesting a role for these miRNAs in the underlying biology in these specific subgroups.
Authors: N Narayan; L Morenos; B Phipson; S N Willis; G Brumatti; S Eggers; N Lalaoui; L M Brown; H J Kosasih; R C Bartolo; L Zhou; D Catchpoole; R Saffery; A Oshlack; G J Goodall; P G Ekert Journal: Leukemia Date: 2016-10-14 Impact factor: 11.528
Authors: M Díaz-Beyá; S Brunet; J Nomdedéu; R Tejero; T Díaz; M Pratcorona; M Tormo; J M Ribera; L Escoda; R Duarte; D Gallardo; I Heras; M P Queipo de Llano; J Bargay; M Monzo; J Sierra; A Navarro; J Esteve Journal: Leukemia Date: 2013-09-27 Impact factor: 11.528
Authors: S Emmrich; J E Katsman-Kuipers; K Henke; M E Khatib; R Jammal; F Engeland; F Dasci; C M Zwaan; M L den Boer; L Verboon; J Stary; A Baruchel; V de Haas; A A Danen-van Oorschot; M Fornerod; R Pieters; D Reinhardt; J H Klusmann; M M van den Heuvel-Eibrink Journal: Leukemia Date: 2013-11-25 Impact factor: 11.528
Authors: Hamilton L Gimenes-Teixeira; Antonio R Lucena-Araujo; Guilherme A Dos Santos; Dalila L Zanette; Priscila S Scheucher; Luciana C Oliveira; Leandro F Dalmazzo; Wilson A Silva-Júnior; Roberto P Falcão; Eduardo M Rego Journal: Exp Hematol Oncol Date: 2013-04-08